13F Holdings
中文EN

RGNX REGENXBIO Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1590877 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.6%
TTM net income YoY1.5%
TTM EPS YoY7.5%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-95.7%
Net margin-113.9%
FCF margin-100.6%
EBITDA margin-85.9%

Returns

ROE-113.2%
ROA-35.4%
ROIC (approx.)-150.2%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.00x
Current ratio4.74x
Interest coverage-4.06x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$170.44M$83.33M$90.24M$112.72M$470.35M
Cost of revenue—$33.57M$37.21M$54.55M$51.83M
Gross profit—$49.76M$53.03M$58.18M$418.51M
R&D expense$228.30M$208.52M$232.27M$242.45M$181.44M
SG&A expense$82.86M$76.62M$88.49M$85.28M$79.33M
Operating income-$161.20M-$233.35M-$268.13M-$262.88M$159.98M
Interest expense$45.01M$12.66M$6.86M$23.25M$26.28M
Pretax income-$193.88M-$227.10M-$263.65M-$280.40M$141.25M
Income tax$0$0-$152,000-$84,000$13.41M
Net income-$193.88M-$227.10M-$263.49M-$280.32M$127.84M
EBITDA-$145.58M-$217.13M-$250.81M-$249.97M$169.54M
EPS (basic)-3.76-4.59-6.02-6.503.01
EPS (diluted)-3.76-4.59-6.02-6.502.91
Weighted avg. shares (diluted)51.57M49.51M43.73M43.15M43.91M
Banking
Provision for credit losses—-$5.00M———
Balance sheet
Cash & equivalents$34.47M$57.53M$34.52M$96.95M$345.21M
Short-term investments$195.60M$177.16M$240.74M$267.69M$112.23M
Receivables$26.38M$20.47M$24.79M$28.08M$32.44M
Current assets$281.28M$278.00M$334.97M$415.98M$518.83M
PP&E, net$104.86M$117.59M$132.10M$141.69M$131.55M
Total assets$453.03M$465.99M$573.97M$833.27M$1.11B
Current liabilities$118.09M$103.19M$130.27M$130.43M$130.47M
Total liabilities$350.30M$206.34M$262.23M$317.07M$349.61M
Shareholders' equity$102.73M$259.65M$311.74M$516.20M$764.30M
Shares outstanding50.89M49.55M44.05M43.30M42.83M
Cash flow statement
Operating cash flow-$123.96M-$173.12M-$218.41M-$207.49M$218.88M
Capital expenditure$2.41M$2.44M$9.96M$30.72M$84.17M
Free cash flow-$126.38M-$175.56M-$228.37M-$238.21M$134.70M
Investing cash flow-$15.87M$103.45M$190.94M-$11.93M-$406.64M
Financing cash flow$116.77M$92.68M-$34.97M-$28.84M$195.25M
Depreciation & amortization$15.62M$16.21M$17.32M$12.91M$9.56M
Stock-based compensation$34.56M$38.46M$40.27M$40.79M$38.81M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.